Activation of muscarinic K+ channels by arecaidine propargyl ester in isolated guinea-pig atrial myocytes.
Arecaidine propargyl ester (APE) was developed as a potential candidate compound for the treatment of Alzheimer's disease. APE has been shown to have cardiovascular effects. APE produces negative chronotropic and inotropic effects in isolated atria. However, the ionic mechanisms underlying the cardiovascular effects of APE in guinea-pig atria are unclear. The aims of this study were: (1) to examine the shortening effect of APE on action potential duration (APD) and to compare the difference in potency between APE and muscarine in isolated single guinea-pig atrial myocytes by using the current clamp method, (2) to examine by using patch clamp techniques the ionic mechanisms underlying the cardiac effects of APE, and (3) to determine whether the cardiac effects caused by APE affect the usefulness of APE as a potential candidate for the treatment of Alzheimer's disease. The APE significantly reduced the APD in guinea-pig atria and produced no direct effect on ventricular myocytes. APE is approximately 20 times as potent as muscarine in shortening the APD. Attenuation of the APD was consistently accompanied by a hyperpolarization of the resting membrane potential in a concentration-dependent manner. The APE activated muscarinic K+ channels and increased potassium conductance in guinea-pig atrial myocytes. In the cell-attached configuration, the APE contained in the pipette increased the channel-opening probability and decreased the closed-state time interval. The proposal that APE can be used as a potential remedy for the treatment of Alzheimer's disease should be taken into consideration the undesirable cardiovascular side effects that APE causes at lower concentrations.
Chen
Hsinyo
H
National Research Institute of Chinese Medicine, #155-1, Sec. 2, Lee-Rong St., Pei-Tou District, Taipei, Taiwan 112, ROC. hsinyo@nricm.edu.tw
D000818:Animals; D001115:Arecoline / Q000031:analogs & derivatives* / Q000494:pharmacology; D051668:Delayed Rectifier Potassium Channels / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006325:Heart Atria / Q000166:cytology*; D007477:Ions; D032342:Muscle Cells / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000737:chemistry; D015221:Potassium Channels / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000378:metabolism*; D013997:Time Factors
D051668:Delayed Rectifier Potassium Channels; D007477:Ions; D015221:Potassium Channels; D011976:Receptors, Muscarinic; C015000:arecaidine esters; D001115:Arecoline; D011188:Potassium